Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5207947
Max Phase: Preclinical
Molecular Formula: C215H298N48O58S7
Molecular Weight: 4707.50
Associated Items:
ID: ALA5207947
Max Phase: Preclinical
Molecular Formula: C215H298N48O58S7
Molecular Weight: 4707.50
Associated Items:
Canonical SMILES: CCCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSCCC(=O)N3CN(CN(C3)C(=O)CCSC[C@@H](C(=O)N[C@@H](C)C(N)=O)NC1=O)C(=O)CCSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCCNC(=O)CCc1cn(CCOCCOCCOCCOCCOCCC(=O)N[C@H]3CSCCC(=O)N4CN5CN(C4)C(=O)CCSC[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc4cccc6ccccc46)NC(=O)[C@@H]4CCCN4C3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@H]3C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@H](C(N)=O)CSCCC5=O)nn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C215H298N48O58S7/c1-10-11-39-142-187(290)245-160(199(302)224-122(2)183(216)286)112-325-90-65-174(274)254-118-252-119-255(120-254)176(276)67-92-327-114-162(202(305)233-147(94-126-31-13-12-14-32-126)190(293)225-123(3)185(288)241-155(103-181(284)285)209(312)259-72-27-46-166(259)205(308)237-148(191(294)229-142)95-127-49-54-134(267)55-50-127)246-192(295)149(96-128-51-56-135(268)57-52-128)238-204(307)165-45-26-71-258(165)208(311)146(232-188(291)144(58-60-178(278)279)231-203(306)164-44-28-73-260(164)210(313)156(104-215(6,7)8)242-200(303)159(226-125(5)266)111-324-89-64-173(252)273)43-22-23-69-220-170(270)59-53-133-107-257(250-249-133)76-78-318-80-82-320-84-86-321-85-83-319-81-79-317-77-61-171(271)227-163-115-328-93-68-177(277)256-117-251-116-253(121-256)175(275)66-91-326-113-161(247-197(300)154(102-180(282)283)236-193(296)150(239-206(309)167-47-29-74-261(167)211(163)314)97-130-35-25-34-129-33-15-16-36-137(129)130)201(304)230-145(62-87-322-9)189(292)228-143(42-21-24-70-221-214(218)219)186(289)235-153(101-179(280)281)196(299)234-151(98-131-105-222-140-40-19-17-37-138(131)140)194(297)243-157(109-264)198(301)248-182(124(4)265)213(316)262-75-30-48-168(262)212(315)263-108-136(269)100-169(263)207(310)240-152(99-132-106-223-141-41-20-18-38-139(132)141)195(298)244-158(184(217)287)110-323-88-63-172(251)272/h12-20,25,31-38,40-41,49-52,54-57,105-107,122-124,136,142-169,182,222-223,264-265,267-269H,10-11,21-24,26-30,39,42-48,53,58-104,108-121H2,1-9H3,(H2,216,286)(H2,217,287)(H,220,270)(H,224,302)(H,225,293)(H,226,266)(H,227,271)(H,228,292)(H,229,294)(H,230,304)(H,231,306)(H,232,291)(H,233,305)(H,234,299)(H,235,289)(H,236,296)(H,237,308)(H,238,307)(H,239,309)(H,240,310)(H,241,288)(H,242,303)(H,243,297)(H,244,298)(H,245,290)(H,246,295)(H,247,300)(H,248,301)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H4,218,219,221)/t122-,123-,124+,136+,142-,143-,144-,145-,146+,147-,148-,149-,150-,151-,152-,153-,154+,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,182-/m0/s1
Standard InChI Key: GTLNVSRQLUUNCK-UOVMZEQOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 4707.50 | Molecular Weight (Monoisotopic): 4703.9890 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N.. (2022) Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology., 65 (14.0): [PMID:35819182] [10.1021/acs.jmedchem.2c00505] |
Source(1):